MicroRNA Regulation of Oncolytic Adenovirus 6 for Selective Treatment of Castration-Resistant Prostate Cancer

Almost all patients with advanced prostate cancer progress to castration-resistant stage with limited treatment options. Oncolytic adenoviruses have been actively pursued as potential agents for cancer treatment. Virtually all clinical trials on oncolytic adenovirus are based on serotype 5. However, viral replication in hepatocytes induces severe liver toxicity and limits its systemic administration for metastatic disease. Moreover, rapid clearance of viral particles injected intravenously further hinders the anticancer efficacy. Adenovirus 6 (Ad6) was previously reported to exhibit less liver toxicity and escape Kupffer cells absorption after systemic administration. To further improve its safety, we generated a novel oncolytic adenovirus Ad6miR, in which four copies of binding sites of a liver-specific microRNA miR122 were incorporated into E1A gene of Ad6. miR122 regulation significantly decreased Ad6 replication in hepatocytes and consequently hepatotoxicity because of the negative regulation of miR122. Cytotoxicity assay using primary or established prostate cancer cell lines showed robust oncolytic activity of Ad6miR. Systemic treatment of established tumors with Ad6miR showed strong antitumor activity, comparable with that of Ad6 or Ad5. Although Ad6 evaded Kupffer cells, its blood clearance rate was as rapid as Ad5. The vast majority of Ad6 particles intravenously injected localized in liver sinusoidal endothelial cells rather than previously reported Kupffer cells. Elevating Ad6miR injection dose increased circulating Ad6miR concentration and its antitumor efficacy. miR122 regulation of Ad6 significantly improves its safety profile after systemic administration, which allows increasing therapeutic doses leading to improved anticancer efficacy of systemic treatment of castration-resistant prostate cancer. Mol Cancer Ther; 11(11); 2410–8. ©2012 AACR.

[1]  E. Wisse,et al.  The role of liver sinusoidal cells in hepatocyte-directed gene transfer. , 2010, The American journal of pathology.

[2]  B. Hirt.  Selective extraction of polyoma DNA from infected mouse cell cultures. , 1967, Journal of molecular biology.

[3]  P. Seth,et al.  Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. , 2011, Human gene therapy.

[4]  Raymond D. Harris,et al.  A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases , 2010, Clinical Cancer Research.

[5]  Ying Di,et al.  MicroRNA Controlled Adenovirus Mediates Anti-Cancer Efficacy without Affecting Endogenous MicroRNA Activity , 2011, PloS one.

[6]  S. Kochanek,et al.  Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  T. Tuschl,et al.  Identification of Tissue-Specific MicroRNAs from Mouse , 2002, Current Biology.

[8]  S. Fawell,et al.  Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  T. Eggerman,et al.  Rapid Kupffer cell death after intravenous injection of adenovirus vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[11]  K. Ghoshal,et al.  Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas , 2006, Journal of cellular biochemistry.

[12]  M. Barry,et al.  Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting , 2011, Current gene therapy.

[13]  M. Gleave,et al.  A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis , 2011, Clinical Cancer Research.

[14]  Stephen L. Brown,et al.  Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  T. Fujiwara,et al.  Enhanced Safety Profiles of the Telomerase-Specific Replication- Competent Adenovirus by Incorporation of Normal Cell-Specific microRNA-Targeted Sequences , 2011, Clinical Cancer Research.

[16]  Sun Mi Park,et al.  MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death , 2008, Oncogene.

[17]  J. Vácha.  Blood volume in inbred strain BALB/c, CBA/J and C57BL/10 mice determined by means of 59Fe-labelled red cells and 59Fe bound to transferrin. , 1975, Physiologia Bohemoslovaca.

[18]  R. Andino,et al.  Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA , 2008, Journal of Virology.

[19]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Horvath,et al.  Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance , 2010, Nature Medicine.

[21]  Jie Tian,et al.  Clearance of Adenovirus by Kupffer Cells Is Mediated by Scavenger Receptors, Natural Antibodies, and Complement , 2008, Journal of Virology.

[22]  M. Barry,et al.  Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  L. Jl,et al.  A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients , 2009, Gene Therapy.

[24]  M. Barry,et al.  Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. , 2009, Virology.

[25]  Jonghan Kim,et al.  Rapid and Efficient Clearance of Blood-borne Virus by Liver Sinusoidal Endothelium , 2011, PLoS pathogens.

[26]  A. Davison,et al.  Toward an Integrated Human Adenovirus Designation System That Utilizes Molecular and Serological Data and Serves both Clinical and Fundamental Virology , 2011, Journal of Virology.

[27]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[28]  C. Napoli,et al.  Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer , 2008, Cell.

[29]  N. Van Rooijen,et al.  Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells , 2009, PLoS pathogens.

[30]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[31]  N. D. Di Paolo,et al.  Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Hongjie Wang,et al.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. , 2010, Blood.

[33]  J. Seppen,et al.  Kupffer cells and not liver sinusoidal endothelial cells prevent lentiviral transduction of hepatocytes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  A. Gerbes,et al.  Role of Kupffer cells in host defense and liver disease , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[35]  E. Small,et al.  A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  D. Montefiori,et al.  Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs , 2010, Journal of Virology.